Subscribe
pills-istock-525984851
sprng23 / iStockphoto.com
9 May 2018Americas

Lannett gains generic product portfolio from Endo subsidiary

Generic drug manufacturer Lannett has acquired the product portfolio of an Endo International subsidiary.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC antitrust charges against Impax dismissed
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
FTC antitrust charges against Impax dismissed
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

More on this story

Americas
FTC antitrust charges against Impax dismissed
25 May 2018   A judge has found it unlikely that Impax Laboratories would launch a generic drug before a final court decision in related patent litigation and has dismissed a case against the company.
Americas
Endo resolves FTC allegations over Lidoderm and Opana ER
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits